March 26 (Reuters) - The U.S. Food and Drug

Administration has approved Novo Nordisk's insulin

injection, Awiqli, to control blood sugar levels in adults

living with type 2 diabetes, the company said on Thursday.

* Novo Nordisk expects to launch the insulin product in the

United States in the second half of 2026.

* The Danish drugmaker said its product is the "first-ever"

once-weekly basal insulin approved by the FDA.

* A once-weekly option reduces injections from seven to one,

which is a major quality-of-life improvement for people with

type 2 diabetes.

* Awiqli is approved in the European Union and 13 more

countries, the company said.